The DOI matches its Crossref record; 242 of the 245 references it cites were found in a registry or an index, and 1 are not checked yet.
Neurodegenerative Tauopathies
Abstract
The defining neuropathological characteristics of Alzheimer's disease are abundant filamentous tau lesions and deposits of fibrillar amyloid beta peptides. Prominent filamentous tau inclusions and brain degeneration in the absence of beta-amyloid deposits are also hallmarks of neurodegenerative tauopathies exemplified by sporadic corticobasal degeneration, progressive supranuclear palsy, and Pick's disease, as well as by hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Because multiple tau gene mutations are pathogenic for FTDP-17 and tau polymorphisms appear to be genetic risk factors for sporadic progressive supranuclear palsy and corticobasal degeneration, tau abnormalities are linked directly to the etiology and pathogenesis of neurodegenerative disease. Indeed, emerging data support the hypothesis that different tau gene mutations are pathogenic because they impair tau functions, promote tau fibrillization, or perturb tau gene splicing, thereby leading to formation of biochemically and structurally distinct aggregates of tau. Nonetheless, different members of the same kindred often exhibit diverse FTDP-17 syndromes, which suggests that additional genetic or epigenetic factors influence the phenotypic manifestations of neurodegenerative tauopathies. Although these and other hypothetical mechanisms of neurodegenerative tauopathies remain to be tested and validated, transgenic models are increasingly available for this purpose, and they…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and a subset of frontotemporal dementia (FTD) are neurodegenerative disorders characterized by tau inclusions in neurons and glia (tauopathies).”
From Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia (2017) · cites this paper as [26]
In the citing paper
“Neurodegenerative tauopathies are characterized by progressive neuronal and glial accumulation in amyloid assemblies of tau protein (Lee et al., 2001).”
From Spontaneous pathology in PS19 tauopathy mice progresses via brain networks (2025) · cites this paper as Lee et al., 2001
In the citing paper
“In the absence of amyloid-beta, NFTs are also implicated in several other neurodegenerative diseases (frontotemporal dementia with parkinsonism, progressive supranuclear palsey, corticobasal degeneration), further supporting the role of tau in the dementing process (Lee et al., 2001).”
From In vivo imaging of tau pathology using multi-parametric quantitative MRI (2015) · cites this paper as Lee et al., 2001
In the citing paper
“Tauopathies include several neurodegenerative diseases such as Pick's disease and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17; reviewed in 1).”
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationA protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Self-citation
Research works printed but not linked: 19
- Arrasate M, 1997, Am. J. Pathol., 151, 1115
- Brion JP, 1985, Arch. Biol., 95, 229
- Feany MB, 1995, Am. J. Pathol., 146, 1388
- 10.1007/s004010050296 · DOI
- 10.1128/mcb.9.4.1381 · DOI
- Hong M, Trojanowski JQ, Lee VM-Y. 2000.Tau-based neurofibrillary lesions.InNeurodegenerative Dementias, ed. CM Clark, JQ Trojanowski, pp. 161–75. New York: McGraw Hill
- 10.1007/s004010050140 · DOI
- Ksiezak-Reding H, 1994, Am. J. Pathol., 145, 1496
- 10.1007/s004010050138 · DOI
- Pickering-Brown S, 2000, Ann. Neurol., 48, 806, 10.1002/1531-8249(200012)48:6<859::aid-ana6>3.0.co;2-1 · DOI
- Rebeiz J, 1967, Trans. Am. Neurol. Assoc., 92, 23
- Rep. Work Group Frontotemporal Dementia Pick's Disease. 2001. Clinical and neuropathological diagnosis of frontotemporal dementias.Neurobiol. Aging.In press
- Shin RW, 1991, Lab. Invest., 64, 693
- Snow AD, 1990, Am. J. Pathol., 137, 1253
- 10.1002/1531-8249(200012)48:6<939::aid-ana17>3.3.co;2-t · DOI
- Trojanowski JQ, 1994, Am. J. Pathol., 144, 449
- 10.1007/s004010050126 · DOI
- Wilhelmsen KC, 1994, Am. J. Hum. Genet., 55, 1159
- Wilson DM, 1997, Am. J. Pathol., 150, 2181
Cited by
Sorted by citations
Items 1,001–1,023 of 1,023
Transcranial LED therapy on amyloid-β toxin 25–35 in the hippocampal region of rats
Eltchechem, C. D. L., Salgado, A. S. I., Zângaro, R. A., Pereira, M. C. D. S., Kerppers, I. I., da Silva, L. A., & Parreira, R. B. (2017) · Lasers in Medical Science · doi:10.1007/s10103-017-2156-3 · Cited by 49
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Davis, G. A., Castellani, R. J., & McCrory, P. (2015) · Neurosurgery · doi:10.1227/neu.0000000000000722 · Cited by 47
Britschgi, M., Takeda-Uchimura, Y., Rockenstein, E., Johns, H., Masliah, E., & Wyss-Coray, T. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-220 · Cited by 45
Weismiller, H. A., Murphy, R., Wei, G., Ma, B., Nussinov, R., & Margittai, M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005316 · Cited by 44
Faulty splicing and cytoskeleton abnormalities in Huntington's disease
Fernández‐Nogales, M., Santos‐Galindo, M., Hernández, I. H., Cabrera, J. R., & Lucas, J. J. (2016) · Brain Pathology · doi:10.1111/bpa.12430 · Cited by 41
Pitavastatin decreases tau levels via the inactivation of Rho/ROCK
Hamano, T., Yen, S.-H., Gendron, T., Ko, L.-W., & Kuriyama, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.020 · Cited by 49
Han, D., Qureshi, H. Y., Lu, Y., & Paudel, H. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901095200 · Cited by 40
Human stem cell-derived neurons: a system to study human tau function and dysfunction
Iovino, M., Patani, R., Watts, C., Chandran, S., & Spillantini, M. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013947 · Cited by 40
Substrate-specific reduction of PP2A activity exaggerates tau pathology
Deters, N., Ittner, L. M., & Götz, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.140 · Cited by 39
Spatial memory deficiency early in 6xTg Alzheimer’s disease mouse model
Kang, S., Kim, J., & Chang, K.-A. (2021) · Scientific Reports · doi:10.1038/s41598-020-79344-5 · Cited by 39
Yang, C., Li, X., Gao, W., Wang, Q., Zhang, L., Li, Y., Li, L., & Zhang, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00682 · Cited by 36
Gardner, L. E., White, J. D., Eimerbrink, M. J., Boehm, G. W., & Chumley, M. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.007 · Cited by 29
Xie, C., Miyasaka, T., Yoshimura, S., Hatsuta, H., Yoshina, S., Kage-Nakadai, E., Mitani, S., Murayama, S., & Ihara, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089796 · Cited by 28
Xie, C., Soeda, Y., Shinzaki, Y., In, Y., Tomoo, K., Ihara, Y., & Miyasaka, T. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13228 · Cited by 27
SWI and phase imaging reveal intracranial calcifications in the P301L mouse model of human tauopathy
Ni, R., Zarb, Y., Kuhn, G. A., Müller, R., Yundung, Y., Nitsch, R. M., Kulic, L., Keller, A., & Klohs, J. (2020) · Magnetic Resonance Materials in Physics, Biology and Medicine · doi:10.1007/s10334-020-00855-3 · Cited by 24
Retromer dysfunction at the nexus of tauopathies
Carosi, J. M., Denton, D., Kumar, S., & Sargeant, T. J. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00727-2 · Cited by 16
A review of proposed mechanisms for neurodegenerative disease
Kelser, B. M., Teichner, E. M., Subtirelu, R. C., & Hoss, K. N. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1370580 · Cited by 20
“While (Lee et al., 2001)-2-fluoro-D-glucose (FDG) has been used since 1979 (Phelps et al., 1979), there are now also tracers for amyloid beta (Krishnadas et al., 2021) and tau (Okamura et al., 2005).”
BackgroundMethodNT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression
Mengel, D., Mok, T. H., Nihat, A., Liu, W., Rissman, R. A., Galasko, D., Zetterberg, H., Mead, S., Collinge, J., & Walsh, D. M. (2021) · Cells · doi:10.3390/cells10123514 · Cited by 12
Daulatzai, M. A. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9528-x · Cited by 12
Leptin Signaling Plays a Critical Role in the Geniposide-Induced Decrease of Tau Phosphorylation
Liu, J., Liu, Z., Zhang, Y., & Yin, F. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv106 · Cited by 11
Spontaneous pathology in PS19 tauopathy mice progresses via brain networks
Ramirez, D. M. O., Whitesell, J. D., Bhagwat, N., Thomas, T. L., Ajay, A. D., Nawaby, A., Delatour, B., Bay, S., LaFaye, P., Harris, J. A., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107072 · Cited by 5
Anti-tau antibodies targeting a conformation-dependent epitope selectively bind seeds
Hitt, B. D., Gupta, A., Singh, R., Yang, T., Beaver, J. D., Shang, P., White, C. L., Joachimiak, L. A., & Diamond, M. I. (2023) · doi:10.1101/2023.05.04.539475 · Cited by 15
Metadata
- Authors
- Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q.
- Affiliations
- MRC Laboratory of Molecular Biology (GB)
- Venue
- Annual Review of Neuroscience
- Publisher
- Annual Reviews
- Published
- 2001-03
- Volume
- 24
- Issue
- 1
- Pages
- 1121-1159
- ISSN
- 0147-006X (ISSN-L)
- 1545-4126
- OpenAlex
- W4230565756
- Semantic Scholar
- 8eb6355272daf41b8da72a5b18a4d8c67d8509cc
- Cited by
- 2,480
- References
- 245
- Citations by year
- 2026: 60 · 2025: 81 · 2024: 102 · 2023: 112 · 2022: 133 · 2021: 130 · 2020: 126 · 2019: 107 · 2018: 114 · 2017: 94 · 2016: 100 · 2015: 115 · 2014: 99 · 2013: 100 · 2012: 92
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- tau protein, tau gene mutations, FTDP-17, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, Alzheimer's disease, tau fibrillization, genetic risk factors, transgenic animal models, neurodegeneration
- MeSH terms
- Animals, Brain, Brain Diseases, Dementia, Humans, Neurofibrillary Tangles, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
